Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)

Once Daily ◽

Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)

American Heart Journal ◽

10.1016/j.ahj.2015.07.006 ◽

2015 ◽

Vol 170 (4) ◽

pp. 675-682.e8 ◽

Cited By ~ 63

Author(s):

Sameer Bansilal ◽

Zachary Bloomgarden ◽

Jonathan L. Halperin ◽

Anne S. Hellkamp ◽

Yuliya Lokhnygina ◽

...

Keyword(s):

Atrial Fibrillation ◽

Vitamin K ◽

Factor Xa ◽

Efficacy And Safety ◽

Direct Factor ◽

Once Daily ◽

Factor Xa Inhibition ◽

Patients With Diabetes

Faculty Opinions recommendation of Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717969218.793469174 ◽

2013 ◽

Author(s):

Jan Amlie ◽

Kristina Hermann Haugaa

Keyword(s):

Risk Factors ◽

Atrial Fibrillation ◽

Renal Dysfunction ◽

Vitamin K ◽

Factor Xa ◽

Direct Factor ◽

Systemic Embolism ◽

Once Daily ◽

Letter by Apostolakis et al Regarding Article, “Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R 2 CHADS 2 Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts”

Circulation ◽

10.1161/circulationaha.112.000708 ◽

2013 ◽

Vol 128 (11) ◽

Cited By ~ 5

Author(s):

Stavros Apostolakis ◽

Deirdre A. Lane ◽

Amitava Banerjee

Keyword(s):

Risk Factors ◽

Atrial Fibrillation ◽

Renal Dysfunction ◽

Vitamin K ◽

Factor Xa ◽

Direct Factor ◽

Systemic Embolism ◽

Once Daily ◽

Correction to: Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)

Circulation ◽

10.1161/cir.0000000000000637 ◽

2018 ◽

Vol 138 (25) ◽

Cited By ~ 1

Keyword(s):

Atrial Fibrillation ◽

Elderly Patients ◽

Vitamin K ◽

Factor Xa ◽

Efficacy And Safety ◽

Direct Factor ◽

Once Daily ◽

Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)

Circulation ◽

10.1161/circulationaha.113.005008 ◽

2014 ◽

Vol 130 (2) ◽

pp. 138-146 ◽

Cited By ~ 206

Author(s):

Jonathan L. Halperin ◽

Graeme J. Hankey ◽

Daniel M. Wojdyla ◽

Jonathan P. Piccini ◽

Yuliya Lokhnygina ◽

...

Keyword(s):

Atrial Fibrillation ◽

Elderly Patients ◽

Vitamin K ◽

Factor Xa ◽

Efficacy And Safety ◽

Direct Factor ◽

Once Daily ◽

Response to Letter Regarding Article, “Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R 2 CHADS 2 Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts”

Circulation ◽

10.1161/circulationaha.113.004013 ◽

2013 ◽

Vol 128 (11) ◽

Cited By ~ 1

Author(s):

Jonathan P. Piccini ◽

Susanna R. Stevens ◽

YuChiao Chang ◽

Daniel E. Singer ◽

Yuliya Lokhnygina ◽

...

Keyword(s):

Risk Factors ◽

Atrial Fibrillation ◽

Renal Dysfunction ◽

Vitamin K ◽

Factor Xa ◽

Direct Factor ◽

Systemic Embolism ◽

Once Daily ◽

Rivaroxaban—Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study

American Heart Journal ◽

10.1016/j.ahj.2009.11.025 ◽

2010 ◽

Vol 159 (3) ◽

pp. 340-347.e1 ◽

Cited By ~ 296

Keyword(s):

Atrial Fibrillation ◽

Vitamin K ◽

Factor Xa ◽

Direct Factor ◽

Once Daily ◽

Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)

The Lancet ◽

10.1016/s0140-6736(14)61836-5 ◽

2015 ◽

Vol 385 (9985) ◽

pp. 2363-2370 ◽

Cited By ~ 74

Author(s):

Jeffrey B Washam ◽

Susanna R Stevens ◽

Yuliya Lokhnygina ◽

Jonathan L Halperin ◽

Günter Breithardt ◽

...

Keyword(s):

Atrial Fibrillation ◽

Retrospective Analysis ◽

Vitamin K ◽

Factor Xa ◽

Cardiovascular Outcomes ◽

Direct Factor ◽

Once Daily ◽

Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial)

The American Journal of Cardiology ◽

10.1016/j.amjcard.2017.03.028 ◽

2017 ◽

Vol 119 (12) ◽

pp. 1989-1996 ◽

Cited By ~ 35

Author(s):

Somasekhara R. Balla ◽

Derek D. Cyr ◽

Yuliya Lokhnygina ◽

Richard C. Becker ◽

Scott D. Berkowitz ◽

...

Keyword(s):

Atrial Fibrillation ◽

Body Mass Index ◽

Body Mass ◽

Vitamin K ◽

Factor Xa ◽

Direct Factor ◽

Once Daily ◽

Factor Xa Inhibition ◽

Atrial Fibrillation Trial

Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion

American Heart Journal ◽

10.1016/j.ahj.2013.12.024 ◽

2014 ◽

Vol 167 (5) ◽

pp. 646-652 ◽

Cited By ~ 19

Author(s):

Michael D. Ezekowitz ◽

Riccardo Cappato ◽

Allan L. Klein ◽

A. John Camm ◽

Chang-Sheng Ma ◽

...

Keyword(s):

Atrial Fibrillation ◽

Vitamin K ◽

Cardiovascular Events ◽

Vitamin K Antagonists ◽

Efficacy And Safety ◽

Once Daily